Metabolic reprograming of cancer as a therapeutic target

被引:5
|
作者
Furukawa, Tatsuhiko [1 ]
Tabata, Sho [2 ]
Minami, Kentaro [3 ]
Yamamoto, Masatatsu [4 ]
Kawahara, Kohichi [4 ]
Tanimoto, Akihide [1 ,5 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pathol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan
[2] Osaka Univ, Inst Prot Res, Lab Cell Syst, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan
[3] Univ Miyazaki Hosp, Dept Pharm, 5200 Kihara Kiyotake Cho, Miyazaki 8891692, Japan
[4] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan
[5] Kagoshima Univ, Ctr Res Adv Diag & Therapy Canc, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2023年 / 1867卷 / 03期
关键词
Anticancer agent; Clinical trial; Drug discovery; Metabolic reprograming; Therapeutic target; PYRUVATE-KINASE M2; AMINO-ACID-METABOLISM; KETONE-BODIES; DOUBLE-BLIND; DIFLUOROMETHYLORNITHINE DFMO; PHASE-III; CELLS; GENE; PROGRESSION; PREVENTION;
D O I
10.1016/j.bbagen.2022.130301
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our understanding of metabolic reprogramming in cancer has tremendously improved along with the technical progression of metabolomic analysis. Metabolic changes in cancer cells proved much more complicated than the classical Warburg effect. Previous studies have approached metabolic changes as therapeutic and/or chemo-preventive targets. Recently, several clinical trials have reported anti-cancer agents associated with metabolism. However, whether cancer cells are dependent on metabolic reprogramming or favor suitable conditions remains nebulous. Both scenarios are possibly intertwined. Identification of downstream molecules and the under-standing of mechanisms underlying reprogrammed metabolism can improve the effectiveness of cancer therapy. Here, we review several examples of the metabolic reprogramming of cancer cells and the therapies targeting the metabolism-related molecules as well as discuss practical approaches to improve the next generation of cancer therapies focused on the metabolic reprogramming of cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] circRNA: A New Biomarker and Therapeutic Target for Esophageal Cancer
    Shoda, Katsutoshi
    Kuwano, Yuki
    Ichikawa, Daisuke
    Masuda, Kiyoshi
    BIOMEDICINES, 2022, 10 (07)
  • [22] Evaluation of FOXC1 as a therapeutic target for basal-like breast cancer
    Mott, Landon
    Su, Kai
    Pack, Daniel W.
    CANCER GENE THERAPY, 2018, 25 (3-4) : 84 - 91
  • [23] NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer
    Nagamatsu, Iori
    Onishi, Hideya
    Matsushita, Shojiro
    Kubo, Makoto
    Kai, Masaya
    Imaizumi, Akira
    Nakano, Kenji
    Hattori, Masami
    Oda, Yoshinao
    Tanaka, Masao
    Katano, Mitsuo
    ANTICANCER RESEARCH, 2014, 34 (1A) : 69 - 80
  • [24] Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target
    van Niekerk, Gustav
    Engelbrecht, Anna-Mart
    CELLULAR ONCOLOGY, 2018, 41 (04) : 343 - 351
  • [25] The Role of LncRNA NEAT1 in Gastric Cancer: Tumor Development and Potential Therapeutic Target
    Zhang, Yi
    Wen, Yu
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (28) : 2213 - 2222
  • [26] Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
    Viswanath, Pavithra
    Chaumeil, Myriam M.
    Ronen, Sabrina M.
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [27] Metabolic Reprograming of Microglia in the Regulation of the Innate Inflammatory Response
    Lauro, Clotilde
    Limatola, Cristina
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [28] Cancer Chemoprevention Locks onto a New Polyamine Metabolic Target
    Gerner, Eugene W.
    CANCER PREVENTION RESEARCH, 2010, 3 (02) : 125 - 127
  • [29] EphA2: A promising therapeutic target in breast cancer
    Zhao, Ping
    Jiang, Dewei
    Huang, Yunchao
    Chen, Ceshi
    JOURNAL OF GENETICS AND GENOMICS, 2021, 48 (04) : 261 - 267
  • [30] Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer
    Caspi, Adi
    Entezari, Ariana A.
    Crutcher, Madison
    Snook, Adam E.
    Waldman, Scott A.
    PERSONALIZED MEDICINE, 2022, 19 (05) : 457 - 472